Two new ACR Clinical Practice Guidelines provide recommendations on the pharmacologic management of JIA, focusing on treatment of oligoarthritis, temporomandibular arthritis & systemic JIA, as well as nonpharmacologic therapies, medication monitoring, immunizations & imaging.
At the 17th Annual Advances in the Diagnosis and Treatment of the Rheumatic Diseases meeting at Johns Hopkins School of Medicine, Baltimore, Atul Deodhar, MD, discussed ankylosing spondylitis and non-radiographic axial spondyloarthritis & clarified common misconceptions about these conditions.
Although effective against rheumatic disease, biologic therapies come with hefty price tags. Patient assistance programs can be a useful resource to help under- and uninsured patients get the drugs they need.
According to research, Pim kinases contribute to the pathogenesis of rheumatoid arthritis (RA) and may have the therapeutic potential for inhibition in patients with RA.
According to a German study presented during ACR Convergence 2021, treatment persistence with JAK inhibitors is comparable to TNF inhibitors and other bDMARDs among patients with rheumatoid arthritis.
Experts shined a spotlight on select abstracts of the latest rheumatology research, addressing such topics as racial disparities in the management of children with SLE, vitamin D or fish oil supplementation to prevent autoimmune disease & more.
Experts share insights into how LDL & HDL levels are affected by inflammation & the treatment of rheumatic disease, addressing how targeting these levels may improve cardiovascular outcomes for patients.
ACR CONVERGENCE 2021—The ACR Convergence 2021 meeting reflected the continued advancement of science and practical research in the field of rheumatoid arthritis (RA). Among the most important topics this year in RA was the evolution of the risk-benefit profile of Janus kinase (JAK) inhibitors, for which new safety data emerged in a series of related…
Neurosarcoidosis & sarcoid dermatopathology are discussed.
Options to escalate treatment for refractory inflammatory myositis and new therapies in the pipeline are discussed.